ADRXADARx Pharmaceuticals

US ExchangeHealth Care2026-09-25

A clinical-stage biotech developing hepatic-targeted siRNA therapeutics for diverse diseases, including HAE and stroke prevention.

$17IPO price

$447MRaised

$19.35Day-1 close

17.29%Day-1 return

A clinical-stage biotech developing hepatic-targeted siRNA therapeutics for diverse diseases, including HAE and stroke prevention.

Company description (source: StockAnalysis)

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention wit...

生物医药医疗健康创新药

51CFO read: Requires deep biotech capital cycle fluency, clinical pipeline valuation modeling, dual FDA/SEC disclosure timing management, and R&D expens

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us